시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 C5 보체 억제제 시장 보고서(2025년)
C5 Complement Inhibitors Global Market Report 2025
상품코드 : 1750933
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,664,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,632,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,600,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

C5 보체 억제제 시장 규모는 향후 수 년간 급성장이 전망될 예정입니다. 예측 기간 동안의 성장은 제약 제조업체 간의 협업, 의료 인프라의 발전, 높은 의료비 지출, 혁신적인 치료법에 대한 수요 증가, 보체 매개 질병의 유병률 증가에 기인할 수 있습니다. 예측 기간 중의 주요 동향으로서는 바이오 테크놀로지의 진보, RNA 베이스의 수법이나 유전자 치료에 대한 투자의 확대, 진단 툴의 개선, 신규 치료법의 출현, 단일클론항체 요법의 개발 등을 들 수 있습니다.

만성 질환의 유병률 증가는 C5 보체 억제제 시장의 성장을 크게 촉진할 것으로 예측됩니다. 만성 질환의 증가는 주로 식단 저하, 신체 활동 부족, 흡연, 스트레스와 같은 생활 습관 요인에 의해 주도되며, 이는 장기적인 건강 악화의 원인이 됩니다. C5 보체 억제제는 보체 시스템의 과활성화를 차단하고 염증을 줄이며 조직 손상을 방지하며, 발작성 야행성 혈색소뇨증(PNH), 비정형 용혈성 요독 증후군(aHUS)과 같은 질환에서 질병 결과를 개선함으로써 만성 질환 치료에 중요한 역할을 합니다. 2022년 10월, 세계심장연맹은 심혈관 질환으로 인한 사망자가 2030년까지 약 2220만 명에서 2050년까지 3230만 명으로 증가할 것으로 예상된다고 보고하여 만성 질환에 대한 부담이 커지고 있음을 강조했습니다.

C5 보체 억제제 시장의 각 회사는 중증 근무력증과 같은 환자에게 편리하고 효과적인 선택을 제공하기 때문에 자기 투여 형 C5 억제제와 같은 혁신적인 치료법 개발에 주력하고 있습니다. 보체 C5 단백질을 표적으로 차단함으로써 염증과 면역 매개 장애를 줄일 수 있습니다. 주목할 만한 예는 2023년 10월 미국 식품의약국(FDA)으로부터 질브리스크(질루코플랜)를 승인받은 것입니다. 유니온 키믹 베르주(UCB) SA가 개발한 이 1일 1회 피하 투여의 C5 보체 억제제는 항아세틸콜린 수용체(AChR) 항체 양성의 전신형 중증근무력증의 성인에게 신 치료 옵션을 제공합니다. 질브리스크 승인은 UCB의 신경 영역에서 포트폴리오를 강화시켜 자가면역 신경근 질환으로 고통받는 환자의 치료 옵션을 넓혀 치료의 편의성을 향상시킵니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

C5 complement inhibitors are a class of targeted immunomodulatory biologic agents that specifically block the cleavage of complement component 5 (C5) into its active fragments, C5a and C5b. By doing so, they prevent the formation of the membrane attack complex (MAC) and mitigate the downstream inflammatory and cytolytic processes linked to the overactivation of the complement system. These inhibitors are used to treat complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and certain forms of generalized myasthenia gravis, where excessive complement activity contributes to disease pathology.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main products in C5 complement inhibitors are long-acting C5 inhibitors and short-acting C5 inhibitors. Long-acting C5 complement inhibitors are therapeutic agents designed to provide prolonged suppression of C5 activity, thereby reducing the frequency of administration while maintaining effective control over immune-mediated conditions. The drugs included in this category are eculizumab, ravulizumab, and others, which can be administered via intravenous, subcutaneous, or oral routes. These inhibitors are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies, with applications in conditions such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder, and others.

The C5 complement inhibitors market research report is one of a series of new reports from The Business Research Company that provides C5 complement inhibitors market statistics, including C5 complement inhibitors industry global market size, regional shares, competitors with a C5 complement inhibitors market share, detailed C5 complement inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the C5 complement inhibitors industry. This C5 complement inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The C5 complement inhibitors market size has grown rapidly in recent years. It will grow from$6.91 billion in 2024 to $7.91 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth during the historic period can be attributed to the rising prevalence of rare and chronic diseases, the growing demand for targeted therapies, increased awareness among healthcare providers, higher investments in research and development, and favorable reimbursement policies.

The C5 complement inhibitors market size is expected to see rapid growth in the next few years. It will grow to$13.45 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth during the forecast period can be attributed to collaborations between drug manufacturers, advancements in healthcare infrastructure, high healthcare expenditure, increasing demand for innovative treatments, and the rising prevalence of complement-mediated illnesses. Key trends during the forecast period include advancements in biotechnology, growing investment in RNA-based methods and gene therapy, improvements in diagnostic tools, the emergence of novel therapies, and developments in monoclonal antibody therapies.

The increasing prevalence of chronic diseases is expected to significantly propel the growth of the C5 complement inhibitors market. Chronic diseases are long-term medical conditions that progress slowly and often require continuous management to prevent complications. The rise in chronic diseases is largely driven by lifestyle factors such as poor diet, physical inactivity, smoking, and stress, which contribute to long-term health deterioration. C5 complement inhibitors play a key role in treating chronic diseases by blocking the overactivation of the complement system, reducing inflammation, preventing tissue damage, and improving disease outcomes in conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and other complement-mediated disorders. For example, in October 2022, the World Heart Federation reported that cardiovascular disease-related deaths are projected to rise from around 22.2 million by 2030 to 32.3 million by 2050, highlighting the growing burden of chronic diseases. This rising prevalence of chronic diseases is a major driver for the expansion of the C5 complement inhibitors market.

Companies in the C5 complement inhibitors market are focusing on developing innovative treatments, such as self-administered C5 inhibitors, to provide more convenient and effective options for patients with generalized myasthenia gravis and other conditions. Self-administered C5 inhibitors are designed for patient use and work by targeting and blocking the complement C5 protein, reducing inflammation and immune-mediated damage. A notable example is the approval of Zilbrysq (zilucoplan) by the U.S. Food and Drug Administration (FDA) in October 2023. This once-daily subcutaneous C5 complement inhibitor, developed by Union Chimique Belge (UCB) SA, provides a new treatment option for adults with generalized myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody-positive. The approval of Zilbrysq strengthens UCB's neurology portfolio, expanding treatment choices for individuals suffering from autoimmune neuromuscular disorders and improving the convenience of treatment.

In July 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired Iveric Bio Inc. for $5.9 billion to enhance its ophthalmology pipeline and strengthen its presence in the retinal disease market. This acquisition grants Astellas access to Iveric Bio's lead asset, Zimura, a complement C5 inhibitor designed to treat geographic atrophy secondary to age-related macular degeneration (AMD). Iveric Bio, a US-based biopharmaceutical company, is developing novel treatments in the complement C5 inhibitor space. The acquisition positions Astellas to further expand its offerings in retinal diseases, potentially improving patient outcomes for those suffering from vision loss associated with complement-mediated conditions.

Major players in the c5 complement inhibitors market are F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis AG, Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., UCB Pharma SA, Swedish Orphan Biovitrum AB(Sobi), Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Omeros Corporation, Dianthus Therapeutics Inc., Kira Pharmaceuticals, Biopharma PEG Scientific Inc., ProbeChem Biochemicals, InflaRx NV, Akari Therapeutics Plc

North America was the largest region in the C5 complement inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the C5 Complement Inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The C5 complement inhibitors market consists of sales of zilucoplan, cemdisiran, tesidolumab, and biologics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

C5 Complement Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on c5 complement inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for c5 complement inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The c5 complement inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. C5 Complement Inhibitors Market Characteristics

3. C5 Complement Inhibitors Market Trends And Strategies

4. C5 Complement Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global C5 Complement Inhibitors Growth Analysis And Strategic Analysis Framework

6. C5 Complement Inhibitors Market Segmentation

7. C5 Complement Inhibitors Market Regional And Country Analysis

8. Asia-Pacific C5 Complement Inhibitors Market

9. China C5 Complement Inhibitors Market

10. India C5 Complement Inhibitors Market

11. Japan C5 Complement Inhibitors Market

12. Australia C5 Complement Inhibitors Market

13. Indonesia C5 Complement Inhibitors Market

14. South Korea C5 Complement Inhibitors Market

15. Western Europe C5 Complement Inhibitors Market

16. UK C5 Complement Inhibitors Market

17. Germany C5 Complement Inhibitors Market

18. France C5 Complement Inhibitors Market

19. Italy C5 Complement Inhibitors Market

20. Spain C5 Complement Inhibitors Market

21. Eastern Europe C5 Complement Inhibitors Market

22. Russia C5 Complement Inhibitors Market

23. North America C5 Complement Inhibitors Market

24. USA C5 Complement Inhibitors Market

25. Canada C5 Complement Inhibitors Market

26. South America C5 Complement Inhibitors Market

27. Brazil C5 Complement Inhibitors Market

28. Middle East C5 Complement Inhibitors Market

29. Africa C5 Complement Inhibitors Market

30. C5 Complement Inhibitors Market Competitive Landscape And Company Profiles

31. C5 Complement Inhibitors Market Other Major And Innovative Companies

32. Global C5 Complement Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The C5 Complement Inhibitors Market

34. Recent Developments In The C5 Complement Inhibitors Market

35. C5 Complement Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기